Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
59pct
3d open
vs 9,698 other HR bills in the 117th — cohort avg 63d
Renal Anemia Innovation Support and Expansion Act or the RAISE Act This bill allows coverage of prescription vitamin and mineral products under the Medicare prescription drug benefit if the products are administered orally and are used to treat iron deficiency anemia in individuals who have chronic kidney disease.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2022 · fourth_quarter · Medicare/Medicaid
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 6973, Enhanced Access to Affordable Medicines Act of 2022 H.R. 7634, Protecting Health Care for All Patients Act of 2022 S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
Referred to the Subcommittee on Health.
Referred to the Subcommittee on Health.
Referred to the Subcommittee on Social Security.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $310,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · fourth_quarter · Medicare/Medicaid
Issues relating to End Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD); S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021; H.R. 4065, To improve the understanding of, and promote access to treatment for, chronic kidney disease, and for other purposes; End-Stage Renal Disease (ESRD) payment reform and quality metrics; S. 377/H.R. 1255, Living Donor Protection Act; H.R. 1676, Jack Reynolds Memorial Medigap Expansion Act H.R. 3893, Coordination, Accountability, Research and Equity for All Kidneys Act of 2021 (CARE for All Kidneys Act); H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act; End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and utilization of calcimimetic drugs; Medicare Secondary Payer; H.R. 7878/S. 4307 Kidney Health Connect Act of 2022; Calendar Year 2023 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Final Rule (CMS-1768-F); H.R. 8594/S. 4750, Restore Protections for Dialysis Patients Act
Client expense: Not reported · Firm income: $70,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2022 · third_quarter · Medicare/Medicaid
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 6973, Enhanced Access to Affordable Medicines Act of 2022 H.R. 7634, Protecting Health Care for All Patients Act of 2022 S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
Client expense: $300,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · third_quarter · Medicare/Medicaid
Issues relating to End Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD); S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021; H.R. 4065, To improve the understanding of, and promote access to treatment for, chronic kidney disease, and for other purposes; End-Stage Renal Disease (ESRD) payment reform and quality metrics; S. 377/H.R. 1255, Living Donor Protection Act; H.R. 1676, Jack Reynolds Memorial Medigap Expansion Act H.R. 3893, Coordination, Accountability, Research and Equity for All Kidneys Act of 2021 (CARE for All Kidneys Act); H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act; End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and utilization of calcimimetic drugs; Medicare Secondary Payer; H.R. 7878/S. 4307 Kidney Health Connect Act of 2022; Calendar Year 2023 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Proposed Rule, issued 6/21/22; H.R. 8594/S. 4750, Restore Protections for Dialysis Patients Act
Client expense: Not reported · Firm income: $70,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Medicare/Medicaid
Issues relating to End Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD); S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021; H.R. 4065, To improve the understanding of, and promote access to treatment for, chronic kidney disease, and for other purposes; End-Stage Renal Disease (ESRD) payment reform and quality metrics; S.377/H.R. 1255, Living Donor Protection Act; H.R. 1676, Jack Reynolds Memorial Medigap Expansion Act H.R. 3893, Coordination, Accountability, Research and Equity for All Kidneys Act of 2021 (CARE for All Kidneys Act); H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act; End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and utilization of calcimimetic drugs; Medicare Secondary Payer; H.R. 7878/S. 4307 Kidney Health Connect Act of 2022; Calendar Year 2023 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Proposed Rule, issued 6/21/22
Client expense: Not reported · Firm income: $70,000
Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
2022 · second_quarter · Medicare/Medicaid
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 6973, Enhanced Access to Affordable Medicines Act of 2022 H.R. 7634, Protecting Health Care for All Patients Act of 2022 S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
Client expense: $320,000 · Firm income: Not reported
2022 · first_quarter · Medicare/Medicaid
Issues relating to End Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD); Implementation of American Rescue Plan Act of 2021 (PL 117-2); Extension of the Medicare Sequester; S. 748, Medicare Sequester Relief Act; Telehealth issues related to COVID-19, including audio-only; S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021; H.R. 4065, To improve the understanding of, and promote access to treatment for, chronic kidney disease, and for other purposes; End-Stage Renal Disease (ESRD) payment reform and quality metrics; Medicare kidney disease education benefit; S.377/H.R. 1255, Living Donor Protection Act; H.R. 1676, Jack Reynolds Memorial Medigap Expansion Act H.R. 3893, Coordination, Accountability, Research and Equity for All Kidneys Act of 2021 (CARE for All Kidneys Act); H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act; End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and utilization of calcimimetic drugs; Kildee/Wenstrup draft legislation to expand the ability of renal dialysis facilities to serve as originating sites for Medicare telehealth services
Client expense: Not reported · Firm income: $70,000
2022 · first_quarter · Medicare/Medicaid
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
Client expense: $320,000 · Firm income: Not reported
2021 · fourth_quarter · Medicare/Medicaid
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
Client expense: $270,000 · Firm income: Not reported
2021 · fourth_quarter · Medicare/Medicaid
Issues relating to End Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD); Implementation of American Rescue Plan Act of 2021 (PL 117-2); Continued monitoring of Consolidated Appropriations Act, 2021 (PL 116-260); Extension of the Medicare Sequester; S. 748, Medicare Sequester Relief Act; Telehealth issues related to COVID-19, including audio-only; S. 150/H.R. 2166, Ensuring Parity in MA for Audio-Only Telehealth Act of 2021; S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021; H.R. 4065, To improve the understanding of, and promote access to treatment for, chronic kidney disease, and for other purposes; End-Stage Renal Disease (ESRD) payment reform and quality metrics; Medicare kidney disease education benefit; End Stage Renal Disease (ESRD) Treatment Choices Model (ETC Model) Proposed Rule (84 FR 34478, 7/18/19); S.377/H.R. 1255, Living Donor Protection Act; H.R. 1676, Jack Reynolds Memorial Medigap Expansion Act H.R. 3893, Coordination, Accountability, Research and Equity for All Kidneys Act of 2021 (CARE for All Kidneys Act); H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act; PL-117-71 Protecting Medicare and American Families from Sequester Cuts Act - specifically: 6 months relief from 2% Medicare sequester, 4% statutory Pay-As-You-Go Act, 1 year relief of physician conversion factor cuts, 1 year delay of clinical lab (PAMA) cuts, delay of radiation oncology demo
Client expense: Not reported · Firm income: $70,000
2021 · third_quarter · Medicare/Medicaid
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
Client expense: $300,000 · Firm income: Not reported
2021 · second_quarter · Medicare/Medicaid
H.R. 1676, Jack Reynolds Memorial Medigap Extension Act; Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act; S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
Client expense: $400,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
| Democratic |
| NC |
| Larry Bucshon | Republican | IN |
| Markwayne Mullin | Republican | OK |
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE